Department of Medicine and Masonic Cancer Center, University of Minnesota; Minneapolis, MN, USA.
Cell Cycle. 2012 Mar 15;11(6):1097-107. doi: 10.4161/cc.11.6.19610.
Despite their genetic diversity, different cancers manifest common features at the protein pathway level. They share a core group of perturbed pathways that converge upon a few regulatory hubs linking the cellular signaling network with the basic metabolic machinery. Available evidence indicates that one such hub is the eIF4F-mediated cap-dependent mRNA translation initiation apparatus, whose integrity is required for physiological control of growth, proliferation and viability. However, when hyperactivated by upstream oncogenic signaling, eIF4F selectively stimulates the translation of a group of mRNAs required for cancer genesis and progression. Here, we describe a model that links the pro-neoplastic function of eIF4F to its ability to disable oncogene-activated tumor surveillance programs and propose a novel therapeutic strategy for cancer based upon targeting aberrant eIF4F with small-molecule antagonists.
尽管存在遗传多样性,不同癌症在蛋白质通路水平上表现出共同特征。它们具有一组共同的受扰通路,这些通路汇聚到少数几个调节枢纽上,这些枢纽将细胞信号网络与基本代谢机制联系起来。现有证据表明,其中一个枢纽是 eIF4F 介导的帽依赖性 mRNA 翻译起始装置,其完整性对于生理控制生长、增殖和存活是必需的。然而,当被上游致癌信号过度激活时,eIF4F 选择性地刺激一组对于癌症发生和进展所必需的 mRNA 的翻译。在这里,我们描述了一个模型,将 eIF4F 的促瘤功能与其能够使致癌基因激活的肿瘤监测程序失活的能力联系起来,并提出了一种基于用小分子拮抗剂靶向异常 eIF4F 的新型癌症治疗策略。